<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Management and prognosis of bullous pemphigoid
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Management and prognosis of bullous pemphigoid
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Management and prognosis of bullous pemphigoid
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Dedee F Murrell, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mae Ramirez-Quizon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John J Zone, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3871854622">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bullous pemphigoid is an autoimmune cutaneous blistering disease characterized by autoantibody deposition at the epithelial basement membrane zone. The disorder most frequently affects older adults and classically presents with generalized, pruritic, urticarial plaques and tense, subepithelial blisters  (
         <a class="graphic graphic_picture graphicRef70352 graphicRef72866 graphicRef79112 graphicRef78910" href="/z/d/graphic/70352.html" rel="external">
          picture 1A-D
         </a>
         ).
        </p>
        <p>
         Topical corticosteroids, systemic corticosteroids, and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         are the mainstays of initial treatment for bullous pemphigoid. Additional immunomodulatory therapies are often added to minimize the adverse effects of chronic corticosteroid therapy or to augment improvement in the disease.
        </p>
        <p>
         The management of bullous pemphigoid will be reviewed here. The epidemiology, pathogenesis, potential triggers, clinical features, and diagnosis of bullous pemphigoid are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">
          "Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of mucous membrane pemphigoid is also reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83575.html" rel="external">
          "Management of mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">
          "Ocular cicatricial pemphigoid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1140896505">
         <span class="h1">
          TREATMENT GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of bullous pemphigoid is generally recommended as the disease can cause discomfort, is a risk factor for infection, and often negatively affects quality of life [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The major goals for the treatment of bullous pemphigoid include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease blister formation and pruritus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Promote healing of blisters and erosions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improve quality of life
        </p>
        <p>
        </p>
        <p>
         These goals are fulfilled through a therapeutic regimen that attenuates autoantibody production and antibody-mediated inflammation while minimizing the risk for serious, drug-induced, adverse effects. In addition, careful skin care and referrals to appropriate specialists for mucosal involvement may help to manage and minimize morbidity. (See
         <a class="local">
          'General skin care'
         </a>
         below and
         <a class="local">
          'Indications for referral'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1524746128">
         <span class="h1">
          PRETREATMENT ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pretreatment evaluation should include assessments for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The possibility of drug-induced bullous pemphigoid
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucosal involvement warranting specialist referral
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3168337514">
         <span class="h2">
          Identification of drug-induced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-induced bullous pemphigoid presents with clinical, histopathologic, and immunopathologic findings consistent with bullous pemphigoid and may develop several months or more than one year after ingestion of the inciting medication [
         <a href="#rid2">
          2
         </a>
         ]. Although drug-induced disease likely accounts for a small proportion of cases of bullous pemphigoid, a wide variety of drugs have been associated with the development of this disease  (
         <a class="graphic graphic_table graphicRef130008" href="/z/d/graphic/130008.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ]. Examples of drugs with the strongest associations with bullous pemphigoid include gliptins, programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, loop diuretics, and penicillins [
         <a href="#rid4">
          4,5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">
          "Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Infections and drugs'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient evaluation
         </strong>
         – The evaluation for drug-induced bullous pemphigoid consists of a careful medication history. Examples of findings that may be more strongly associated with drug-induced bullous pemphigoid than classic bullous pemphigoid include younger patient age, the development of bullae on normal-appearing skin, and histopathologic findings of intraepidermal vesicles, necrotic keratinocytes, or thrombus formation [
         <a href="#rid3">
          3
         </a>
         ]. Similar to classic bullous pemphigoid, pruritus and eczematous lesions may precede blistering.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug management
         </strong>
         – Drugs suspected of inducing bullous pemphigoid should be promptly discontinued whenever feasible. In addition, patients typically require the initiation of medical therapy to suppress cutaneous inflammation and blistering. Similar to classic bullous pemphigoid, topical and systemic corticosteroids are the mainstays of treatment. (See
         <a class="local">
          'Approach to management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data from case reports and case series suggest that many patients respond rapidly to medical treatment and cessation of the inciting drug, achieving remission within six weeks, after which treatment can be tapered [
         <a href="#rid3">
          3
         </a>
         ]. However, other patients develop a chronic and persistent course, resembling classic bullous pemphigoid [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Approach to management'
         </a>
         below and
         <a class="local">
          'Initial therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further study is necessary to clarify the impact of the cessation of gliptin therapy. Although the time to achieve disease control and relapse rates did not differ among patients who ceased or continued gliptin therapy in a retrospective study that included 108 patients with gliptin-associated bullous pemphigoid, a retrospective study of 40 patients with gliptin-associated bullous pemphigoid found a higher rate of complete remission after three months among patients who ceased gliptin therapy (65 versus 5 percent) [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1709832355">
         <span class="h2">
          Indications for referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of bullous pemphigoid is a multidisciplinary affair that ideally consists of management by a dermatologist in conjunction with the patient's primary care clinician.
        </p>
        <p>
         When there is known or suspected mucosal involvement of the ocular, esophageal, pharyngeal, or laryngeal mucosa, referral to appropriate specialists is advised:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ophthalmology
         </strong>
         – Prompt referral is indicated for patients with signs of ocular involvement. Examples of suggestive findings include itching or burning sensations in the eyes or visual changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastroenterology
         </strong>
         – Referral to a gastroenterologist for assessment for esophageal involvement is indicated for patients with dysphagia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Otolaryngology
         </strong>
         – Referral to an otolaryngologist is indicated for patients with signs of laryngeal, pharyngeal, or nasal mucosa involvement. Hoarseness of the voice or difficulty speaking suggest laryngeal involvement. Pharyngeal involvement may present with dysphagia. Symptoms of nasal obstruction may suggest nasal involvement.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3595341037">
         <span class="h1">
          APPROACH TO MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1572546171">
         <span class="h2">
          Overview of therapeutic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunosuppressants and other anti-inflammatory medications are the mainstays of pharmacologic therapy for bullous pemphigoid. Patients may require treatment for up to several years.
         <strong>
         </strong>
        </p>
        <p>
         Much of the morbidity and mortality related to bullous pemphigoid results from the combined effect of patient comorbidities and adverse effects of treatment, rather than from direct effects of the disease. Therefore, treatment should be conservative, incorporating the minimal amount of medication required to achieve remission and careful consideration of drug toxicity.
        </p>
        <p class="headingAnchor" id="H1532385650">
         <span class="h3">
          Selection of initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment for bullous pemphigoid typically consists of one of the following as the primary mode of therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-potency topical corticosteroid (eg,
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral corticosteroid (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
        </p>
        <p>
        </p>
        <p>
         Each of these approaches is appropriate, with efficacy data to support achievement of disease control in a majority of patients. Consideration of feasibility of treatment, risk for adverse effects, relative efficacy, and patient preference influence selection.
        </p>
        <p>
         Although high-potency topical corticosteroid therapy (twice-daily application of
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate) is highly effective for bullous pemphigoid and associated with lower mortality and risk for severe complications compared with oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (1 mg/kg per day) in patients with extensive bullous pemphigoid [
         <a href="#rid8">
          8
         </a>
         ], challenges with administration limit use of this approach to therapy in some settings. Adherence to topical corticosteroid therapy can be challenging, with treatment success dependent upon the ability of a patient of advanced age or a caregiver to apply a topical corticosteroid to extensive areas of skin daily. The preference or need for an easily administered treatment commonly leads to the selection of an oral corticosteroid or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         for initial therapy. (See
         <a class="local">
          'Initial therapy'
         </a>
         below.)
        </p>
        <p>
         For patients for whom topical corticosteroid monotherapy is not utilized, selection between
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         often rests upon consideration of tolerance for risk for adverse effects and disease severity. Doxycycline may be less likely to induce rapid remission compared with oral prednisone but has a more favorable side effect profile [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Tetracyclines'
         </a>
         below.)
        </p>
        <p>
         The favorable side effect profile prompts us to select
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , rather than oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , for the initial treatment of milder presentations of bullous pemphigoid (eg, localized bullous pemphigoid or development of only a few new bullae per day). We typically add use of a topical corticosteroid on affected areas in an attempt to augment the response to doxycycline. Other tetracyclines, such as
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , are alternatives to doxycycline. Doxycycline and other tetracyclines are sometimes given in conjunction with
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         (niacinamide), an active form of vitamin B3 with anti-inflammatory properties. (See
         <a class="local">
          'Tetracyclines'
         </a>
         below.)
        </p>
        <p>
         Clinician approaches to extensive disease (eg, widespread skin involvement or development of many new bullae per day) differ. While some experts consider oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         the preferred initial oral treatment for this population, others consider a trial of oral
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         a reasonable initial approach given data supporting efficacy in some extensive bullous pemphigoid patients and the drug's favorable side effect profile [
         <a href="#rid9">
          9
         </a>
         ]. Limited data suggest that initial treatment with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         may also be effective as a primary treatment for bullous pemphigoid [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H623042567">
         <span class="h3">
          Incorporation of corticosteroid-sparing therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the chronic nature of bullous pemphigoid and the multiple adverse effects of systemic corticosteroids, corticosteroid-sparing agents (eg,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ) are often added to an oral corticosteroid regimen following achievement of disease control in an attempt to facilitate corticosteroid tapering. Alternatively, given the common delay in onset of effect of corticosteroid-sparing therapies, the corticosteroid-sparing agent and oral corticosteroid are started simultaneously. (See
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         below and
         <a class="local">
          'Corticosteroid-sparing therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Immunosuppressive corticosteroid-sparing therapies, such as
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , are often reserved for patients who presented with extensive bullous pemphigoid (eg, widespread skin involvement or development of many new bullae per day). The decision to add an immunosuppressant should not be taken lightly given that these drugs may cause serious adverse effects. In some older adults, the risks of adding a corticosteroid-sparing immunosuppressant may exceed those of maintaining low-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy (eg, 5 mg per day or less). (See
         <a class="local">
          'Corticosteroid-sparing therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H37102252">
         <span class="h3">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic options for bullous pemphigoid refractory to the treatments above include a variety of biologic therapies. Examples include
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          dupilumab
         </a>
         , and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG). We typically use these therapies when patients fail to respond to standard therapy, morbidity from systemic corticosteroid therapy occurs, or tapering of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to less than 10 mg per day is not feasible despite use of corticosteroid-sparing therapies. (See
         <a class="local">
          'Refractory disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3365767756">
         <span class="h2">
          Assessing response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary method for assessing the response of bullous pemphigoid to treatment is the clinical assessment. Specific features to assess include the presence of skin lesions of bullous pemphigoid, the occurrence of new lesion development or lesion expansion, the rate of healing of existing lesions, the presence of pruritus, and the current medication regimen. For patients in whom pre-existing skin lesions, the development of new or expanding skin lesions, or pruritus have resolved, the duration of resolution should also be assessed. (See
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         below.)
        </p>
        <p>
         Comparing baseline serum bullous pemphigoid antibody levels with subsequent levels may have value as an adjunct to clinical assessment. The level of bullous pemphigoid antigen 180 (BP180) antibodies in serum usually correlates with the clinical activity of bullous pemphigoid [
         <a href="#rid11">
          11,12
         </a>
         ]. In addition, marked decreases in BP180 antibody levels and lesser decreases in bullous pemphigoid antigen 230 (BP230) antibody levels have been detected soon after the start of topical corticosteroid treatment [
         <a href="#rid13">
          13
         </a>
         ]. Limited data suggest an association between BP180 antibody levels and risk for relapse [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         below and
         <a class="local">
          'Prognosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Enzyme-linked immunosorbent assay'
         </a>
         .)
        </p>
        <p>
         Use of precise descriptors of response is recommended for clinical studies. In 2012, a panel of international experts proposed unifying outcome definitions to support comparisons of therapeutic outcomes of studies [
         <a href="#rid16">
          16
         </a>
         ]. The validated score known as the Bullous Pemphigoid Disease Area Index (BPDAI) is used in specialized clinics for bullous pemphigoid patients to quantify their responses to treatments. The BPDAI activity score correlates well with the BP180 antibody titer.
        </p>
        <p class="headingAnchor" id="H4136193296">
         <span class="h2">
          Treatment tapering and cessation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical assessment guides the timing for tapering or cessation of therapy. The primary finding that supports the initiation of tapering is referred to as the "end of the consolidation phase" in clinical studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          End of the consolidation phase
         </strong>
         – No new lesions or pruritic symptoms have occurred for at least two weeks, and most (approximately 80 percent) of established lesions have healed [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although data to confirm the best approach to the use of serum antibody levels to guide therapy are lacking, observed correlations among antibody levels, clinical activity, and disease relapse have contributed to the use of periodic measurement of serum BP180 antibody levels as an adjunct to the physical examination in clinical practice [
         <a href="#rid11">
          11-15
         </a>
         ]. Approaches have included awaiting substantial reductions from pretreatment levels to support reductions in therapy and following trends in an attempt to predict disease exacerbations that may warrant increases in therapy. Additional study is needed to explore the use of BP180 antibody levels for informing changes in therapy. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above.)
        </p>
        <p>
         Tapering is generally performed slowly, with progressive reductions of treatment doses (eg, 5 mg reduction in
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose) every two to four weeks in conjunction with close clinical follow-up. Tapering continues provided 80 percent of lesions have healed, there are less than three lesions that heal spontaneously within one week, and there is no pruritus. Awaiting blister-free skin prior to tapering may prolong treatment and increase risk for treatment-related side effects, particularly with oral corticosteroids.
        </p>
        <p>
         Discontinuation of treatment may be attempted once patients have remained in complete remission (absence of new or established lesions or pruritus) on minimal therapy for at least two months [
         <a href="#rid16">
          16
         </a>
         ]. Examples of doses considered minimal therapy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          Clobetasol
         </a>
         propionate – ≤20 g of clobetasol propionate per week
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         – ≤0.1 mg/kg per day
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         – ≤0.7 mg/kg per day (patients with normal thiopurine S-methyltransferase [TPMT] level)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil – ≤500 mg per day
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mycophenolic acid – ≤360 mg per day
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         – ≤5 mg per week
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         – ≤50 mg per day
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         – 100 mg twice daily
        </p>
        <p>
        </p>
        <p>
         Our general approach to recurrences during tapering or following treatment cessation is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence of mild disease activity (eg, &lt;3 new lesions within one month)
         </strong>
         – Return to the preceding lowest effective treatment dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence of greater than mild disease activity (eg, development of ≥3 lesions per month that do not heal within one week, extension of established lesions, or daily pruritus)
         </strong>
         – Return to dose that preceded the last effective treatment dose; if this fails or patient presented with extensive disease activity, return to initial effective dose. Add a corticosteroid-sparing systemic agent for patients who are not already receiving one and change the corticosteroid-sparing agent for patients who are already receiving one.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2105148804">
         <span class="h2">
          Determining treatment failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment failure may be defined as continued development of nontransient lesions, continued extension of existing lesions, failure of existing lesions to begin to heal, or continued pruritus despite an adequate course of treatment.
        </p>
        <p>
         Bullous pemphigoid tends to respond to treatment quickly, usually within one month of receipt of appropriate therapeutic doses. Examples of points after which treatment failure may be assumed include [
         <a href="#rid16">
          16
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          Clobetasol
         </a>
         propionate – 40 g per day for four weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         – 0.75 mg/kg per day for at least three weeks (with or without other therapies)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         – 2.5 mg/kg per day for four weeks (patients with normal TPMT levels)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil – 40 mg/kg per day for four weeks (patients with normal renal function)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         – 15 mg per week for four weeks (patients &gt;60 kg and without major renal impairment)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         – 1.5 mg/kg per day for four weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tetracyclines – Full therapeutic dosing for four weeks
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1936170150">
         <span class="h2">
          General skin care
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best approach to the care of blistered skin is not established. In our experience, daily rupturing of tense blisters seems to reduce lateral extension of the blister edges.
        </p>
        <p>
         We instruct patients and caregivers to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cleanse blisters with alcohol prior to rupturing them with a sterile needle or blade. The puncture is best placed in the most gravitationally dependent area of the blister to facilitate drainage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leave the overlying epithelial layer (blister roof) in place. The epithelium acts as a natural wound dressing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cover open erosions with nonstick dressings to reduce pain and risk for infection.
        </p>
        <p>
        </p>
        <p>
         Superinfection is a significant concern in patients with bullous pemphigoid, particularly when numerous skin lesions are present and systemic immunosuppressants are being utilized for treatment. Patients and caregivers should be informed about the warning signs of infection (eg, purulent drainage, worsening redness, or pain) to facilitate prompt diagnosis and treatment.
        </p>
        <p class="headingAnchor" id="H3561429417">
         <span class="h2">
          Oral involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral mucosal involvement, which usually manifests as oral erosions, occurs in 10 to 30 percent of patients with bullous pemphigoid [
         <a href="#rid17">
          17
         </a>
         ]. Similar to mucous membrane pemphigoid, oral mucous membrane involvement in bullous pemphigoid can often be managed with topical corticosteroid therapy. (See
         <a class="medical medical_review" href="/z/d/html/83575.html" rel="external">
          "Management of mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p>
         In addition, our experience suggests that mucous membrane involvement frequently improves during systemic therapy for cutaneous disease.
        </p>
        <p class="headingAnchor" id="H24368200">
         <span class="h1">
          INITIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corticosteroids, administered topically or systemically, and oral
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         are the mainstays of initial therapy. (See
         <a class="local">
          'Selection of initial treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H24368207">
         <span class="h2">
          Topical corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-potency topical corticosteroids (group 1) are utilized for bullous pemphigoid  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 2
         </a>
         ). The ability of patients to obtain and administer topical therapy is a major factor for selection of this mode of therapy (see
         <a class="local">
          'Selection of initial treatment'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – A superpotent topical corticosteroid, such as
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% cream, is typically applied twice daily. Patients with generalized or widespread involvement apply 20 to 30 g of clobetasol propionate per day to the entire skin surface of the trunk and extremities. Patients with limited skin involvement can apply treatment to the affected areas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Achievement of disease control is expected within one month. Patients who fail to improve are transitioned to systemic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who achieve stable disease control are candidates for treatment tapering. We typically begin to taper topical corticosteroid use after two weeks of stable disease control and progressively reduce the frequency of application. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Determining treatment failure'
         </a>
         above and
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The cost of topical corticosteroids (generally higher than
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) and limited access to these agents may inhibit the use of topical corticosteroids in some clinical settings. In the United States, cost often inhibits use of topical corticosteroids as the primary therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Randomized trials have compared
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate with systemic corticosteroid therapy as well as different regimens of clobetasol propionate therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical versus systemic corticosteroids
         </strong>
         – The use of topical corticosteroids as monotherapy for bullous pemphigoid is supported by a multicenter, randomized trial (n = 341) that found that patients with extensive bullous pemphigoid (n = 188, defined as &gt;10 new bullae per day) treated with topical
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% cream had better clinical outcomes than patients with extensive bullous pemphigoid treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ]. This included higher one-year survival rates (76 versus 58 percent), a higher likelihood of achieving disease control by day 21 (99 versus 91 percent), and a lower frequency of severe complications (29 versus 54 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Among the patients with moderate bullous pemphigoid (n = 153, defined as ≤10 new bullae per day), the differences between the topical and systemic therapy groups for one-year survival (both 69 percent), likelihood of disease control by day 21 (100 versus 95 percent, respectively), and severe complications (32 versus 38 percent, respectively) were not statistically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The regimen for
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% cream consisted of a total daily dose of 40 g that was given through twice-daily applications of clobetasol to the entire cutaneous surface.
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         was given as 0.5 mg/kg per day for moderate disease and 1 mg/kg per day for severe disease. Treatment was continued in this manner until 15 days after disease control. Subsequently, clobetasol was gradually reduced over the course of 12 months. The dose of prednisone was reduced by 15 percent every three weeks until treatment was discontinued after 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Higher versus lower doses of
         </strong>
         <strong>
          clobetasol
         </strong>
         <strong>
          propionate
         </strong>
         – The findings of a randomized trial suggest that doses lower than 40 g per day of
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate may be sufficient for achieving disease control [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a randomized trial that included 312 patients with newly diagnosed bullous pemphigoid treated with
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate 0.05% cream, a milder regimen (10 to 20 g per day for moderate disease and 20 to 30 g per day for extensive disease until 15 days after disease control, then tapered to discontinuation over four months) was as effective for attaining control of moderate and extensive bullous pemphigoid as the regimen used in the trial above (40 g per day tapered slowly over 12 months) [
         <a href="#rid18">
          18
         </a>
         ]. Disease control was achieved by day 21 in 98 versus 100 percent of patients, respectively. Relapses were more likely to occur during the one-year trial in patients in the less aggressive treatment group; however, this group discontinued treatment after 4 months rather than 12 months. One-year, disease-free survival rates were 30 versus 45 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         After adjustments were made for patient age and general health status (Karnofsky score), a statistically significant reduction in the risk for mortality and life-threatening, adverse effects was detected among patients with moderate bullous pemphigoid who were treated with the milder regimen compared with those treated with the higher-dose regimen (hazard ratio [HR] 0.54, 95% CI 0.30-0.97). A significant difference in these factors was not seen among patients with extensive disease (HR 1.18, 95% CI 0.76-1.82).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         – High-potency topical corticosteroids can result in cutaneous atrophy, striae, and folliculitis. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Cutaneous'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Adrenal suppression is an additional concern with the extensive application of topical corticosteroids [
         <a href="#rid19">
          19-21
         </a>
         ]. However, among a subset of 28 patients evaluated for adrenal suppression in the dose-comparison trial above, only 5 of 18 patients in the mild regimen group (28 percent) and 1 of 8 patients in the higher-dose regimen group (12 percent) had positive cosyntropin tests (an indicator of adrenal sufficiency) after seven days of therapy [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Systemic'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The adverse effects of topical corticosteroids are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1699192073">
         <span class="h2">
          Systemic corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic corticosteroids are typically administered orally.
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          Prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         are commonly prescribed, though other formulations may also be effective [
         <a href="#rid22">
          22,23
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The optimal regimen for systemic corticosteroid therapy is unclear. We typically treat patients with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         with starting doses ranging from 0.5 mg/kg to 0.75 mg/kg per day, with the initial starting dose dependent on the severity of disease and patient comorbidities. The need for measures to reduce risk for treatment-related complications, such as osteoporosis or gastrointestinal adverse effects, should be reviewed. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'General treatment considerations and monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The response to treatment is usually rapid. In one randomized trial that compared treatment with
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate with treatment with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , 95 and 91 percent of patients with moderate or extensive bullous pemphigoid, respectively, who were treated with prednisone (0.5 to 1 mg/kg per day) achieved disease control by 21 days [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If patients do not demonstrate improvement within two to three weeks, we typically add a corticosteroid-sparing systemic agent (if the patient is not already receiving one) and increase the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         to 0.75 mg/kg per day for patients receiving less than 0.75 mg/kg per day. (See
         <a class="local">
          'Corticosteroid-sparing therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following achievement of disease control, the systemic corticosteroid can be tapered slowly, typically over the course of several months. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         above and
         <a class="local">
          'Determining treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – A trial in which patients with bullous pemphigoid (n = 341) were randomly assigned to either
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         propionate or oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy supports the efficacy of prednisone for achieving disease control in patients with bullous pemphigoid [
         <a href="#rid8">
          8
         </a>
         ]. However, compared with clobetasol propionate, prednisone therapy was associated with a slightly lower likelihood of achieving disease control at day 21, lower one-year survival rates, and greater risk for severe complications among patients with extensive bullous pemphigoid (patients developing &gt;10 new bullae per day). Details of this trial are described above. (See
         <a class="local">
          'Topical corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The findings of another randomized trial suggest that doses greater than 0.75 mg/kg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         per day may not be more effective for achieving disease control. A multicenter, randomized trial (n = 50) that compared starting prednisolone doses of 0.75 mg/kg per day and 1.25 mg/kg per day for bullous pemphigoid did not find a statistically significant difference in the proportion of patients in the 0.75 mg/kg group and the 1.25 mg/kg group who achieved clear skin by day 21 (58 versus 64 percent, respectively) [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Systemic corticosteroid therapy can lead to serious acute and long-term side effects [
         <a href="#rid25">
          25
         </a>
         ]. The adverse effects of systemic corticosteroid therapy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Certain populations have elevated risk for systemic corticosteroid side effects. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'Assessment for preexisting comorbid conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Measures to prevent osteopenia should be implemented in patients receiving chronic systemic corticosteroid therapy. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2181224722">
         <span class="h2">
          Tetracyclines
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          Tetracycline
         </a>
         antibiotics (eg,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         , tetracycline,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ), alone or in combination with
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         (niacinamide), have been utilized for the treatment of bullous pemphigoid [
         <a href="#rid26">
          26-32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – We typically treat adults with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         at a dose of 100 mg twice daily. Alternatives to doxycycline include
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         100 mg twice daily and
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         500 mg four times daily, although availability of tetracycline is limited. We treat with doxycycline based upon greater evidence to support efficacy and a more favorable side effect profile in comparison with minocycline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether coadministration of
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         antibiotics with
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         is superior to treatment with a tetracycline antibiotic alone is unclear. We do not typically add nicotinamide. Studies of tetracycline for bullous pemphigoid have often included coadministration with nicotinamide, but nicotinamide was not used in a randomized trial that compared
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         with oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Few randomized trials have evaluated these therapies.
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         was beneficial in a randomized trial that compared doxycycline and oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (BLISTER trial). In the trial, 253 adults with bullous pemphigoid (with at least three clinically significant blisters) were randomly assigned to receive either doxycycline (200 mg per day) or prednisolone (0.5 mg/kg per day) as initial treatment [
         <a href="#rid9">
          9
         </a>
         ]. Application of a potent topical corticosteroid (
         <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">
          mometasone
         </a>
         furoate) to active lesions was permitted during the first three weeks and after six weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At six weeks,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         was noninferior to
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         based upon the specified noninferiority margin of a 37 percent difference in effect. In the doxycycline group, 83 of 112 patients (74 percent) achieved treatment success (three or fewer significant blisters) compared with 92 of 101 patients (91 percent) in the prednisolone group. The adjusted difference in effect was 18.6 percent (90% CI 11.1-26.1). In addition, over 52 weeks, fewer severe, life-threatening, or fatal events occurred in the doxycycline group than in the prednisolone group (22 of 121 patients [18 percent] compared with 41 of 113 patients [36 percent], respectively). The adjusted difference in effect was 19 percent (95% CI 7.9-30.1).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, a small, unblinded, randomized trial did not find significant differences in efficacy between
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          nicotinamide
         </a>
         in patients with bullous pemphigoid. In the randomized trial (n = 20), eight weeks of tetracycline (500 mg four times per day) plus nicotinamide (500 mg three times per day) was compared with prednisone (40 to 80 mg per day) [
         <a href="#rid29">
          29
         </a>
         ]. Out of the 14 patients treated with tetracycline and nicotinamide, there were five complete responses, five partial responses, one failure to respond, and one case of worsening disease. Two patients were unavailable for follow-up. Among the six patients treated with prednisone, one had a complete response and the remainder responded partially to therapy. A larger, blinded, randomized trial is necessary to confirm the comparative efficacy of these regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Common side effects of tetracyclines include photosensitivity and gastrointestinal distress. Long-term treatment with tetracyclines is contraindicated in children under the age of nine years due to adverse effects on tooth development.
         <a class="drug drug_general" data-topicid="9696" href="/z/d/drug information/9696.html" rel="external">
          Nicotinamide
         </a>
         therapy is occasionally associated with headaches or gastrointestinal distress.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24368221">
         <span class="h1">
          CORTICOSTEROID-SPARING THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data to support the efficacy of drugs (eg, tetracyclines,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ) for corticosteroid-sparing therapy in bullous pemphigoid are limited. However, in clinical practice, these drugs are commonly used to facilitate tapering and discontinuation of oral corticosteroids. The corticosteroid-sparing agent is often added a few weeks prior to the start of tapering or at the start of oral corticosteroid therapy.
        </p>
        <p class="headingAnchor" id="H1868569621">
         <span class="h2">
          Selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tolerability of nonimmunosuppressant agents, such as
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         , makes them favorable options for corticosteroid-sparing therapy, particularly for patients with milder presentations of bullous pemphigoid (eg, localized disease or history of active disease manifesting as only a few new blisters per day) and patients who are unlikely to tolerate risks of immunosuppressive therapy.
        </p>
        <p>
         Immunosuppressants, such as
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , are typically reserved for patients with a history of extensive bullous pemphigoid (eg, widespread skin involvement or development of many new bullae per day) or patients who fail to improve with or cannot tolerate nonimmunosuppressive, corticosteroid-sparing therapies. We typically attempt treatment with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         prior to considering use of immunosuppressant therapies.
        </p>
        <p class="headingAnchor" id="H463090508">
         <span class="h2">
          Tetracyclines
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to use as primary therapies for bullous pemphigoid,
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         antibiotics can also be employed as corticosteroid-sparing agents. Dosing is similar to use as primary therapy. Efficacy data, treatment regimens, and adverse effects for tetracyclines are reviewed above. (See
         <a class="local">
          'Tetracyclines'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4283515563">
         <span class="h2">
          Dapsone
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
         is usually initiated at a low dose (eg, 25 or 50 mg per day in adults) and titrated upward as tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Support for a corticosteroid-sparing effect of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         comes from an open trial in which 54 patients with bullous pemphigoid were randomly assigned to receive
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (0.5 mg/kg per day) in combination with either
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (1.5 or 2.5 mg/kg per day based upon thiopurine S-methyltransferase [TPMT] activity) or dapsone (1.5 mg/kg per day) [
         <a href="#rid33">
          33
         </a>
         ]. Methylprednisone was tapered to discontinuation as tolerated prior to tapering azathioprine or dapsone. Five patients in the azathioprine group and three patients in the dapsone group achieved the primary endpoint of discontinuation of methylprednisolone after a median time of 251 and 81 days, respectively. There was a nonstatistically significant trend towards a lower median cumulative methylprednisolone dose in the dapsone group compared with the azathioprine group (1.92 versus 2.65 g). The small study size may have contributed to the lack of statistical significance. The number of adverse effects was similar in the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional support for benefit of
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         comes from a 2009 review of published case reports and case series that found clinical improvement documented in 139 of 170 patients who were treated with dapsone (50 to 300 mg per day) alone or in combination with topical corticosteroids, systemic corticosteroids, or immunosuppressive agents [
         <a href="#rid34">
          34
         </a>
         ]. In particular, the efficacy of dapsone as monotherapy was reviewed in a retrospective series of 36 patients with bullous pemphigoid. Among 15 patients treated with dapsone alone (50 to 200 mg per day), 20 percent appeared to respond to therapy, with 7 percent achieving complete remission [
         <a href="#rid35">
          35
         </a>
         ]. Patients who were concomitantly treated with topical corticosteroids and dapsone (n = 19) seemed to have better outcomes; the rates of response and complete response were 63 and 47 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and monitoring
         </strong>
         – Examples of adverse effects include hemolytic anemia, methemoglobinemia, agranulocytosis, hypersensitivity, hepatotoxicity, and motor neuropathy. Severe hemolytic anemia may occur in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency during treatment with
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         . We evaluate patients for G6PD deficiency prior to initiating dapsone therapy. Laboratory monitoring for hematologic toxicity is indicated for all patients, particularly early in the course of treatment. (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24368235">
         <span class="h2">
          Azathioprine
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Doses between 0.5 and 2.5 mg/kg per day are typically used [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk for toxicity among individuals influences the appropriate dosing of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , particularly in relation to
         <em>
          TPMT
         </em>
         and nucleoside diphosphate-linked moiety X motif 15 (
         <em>
          NUDT15
         </em>
         ) gene polymorphisms associated with increased risk for toxicity. Although routine testing for these gene polymorphisms prior to treatment with azathioprine is advocated by some experts, factors such as varying prevalence of these polymorphisms among populations and the occurrence of myelosuppression in patients without these polymorphisms lead other experts to disagree. (See
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically perform genotyping for
         <em>
          TPMT
         </em>
         and
         <em>
          NUDT15
         </em>
         polymorphisms prior to treatment and follow dosing recommendations outlined by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcpicpgx.org%2Fguidelines%2F&amp;token=zjLVfmxyYF0zItjS0b9hzQp3Faz0%2BWCW6l9Rg5YKBf7TjzsY0v3ShgUPQ7%2BkCw3y&amp;TOPIC_ID=15297" target="_blank">
          Clinical Pharmacogenetics Implementation Consortium
         </a>
         guideline. If such testing is not feasible, we typically start with 0.5 mg/kg per day and monitor patients closely for hematologic toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Responses to treatment can occur within one month. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         above and
         <a class="local">
          'Determining treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Efficacy data for
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         are limited [
         <a href="#rid36">
          36-39
         </a>
         ]. Although a randomized trial that compared azathioprine plus
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         with treatment with the same regimen of prednisolone given alone did not find that the addition of azathioprine increased the likelihood of achieving disease control [
         <a href="#rid37">
          37
         </a>
         ], a separate randomized trial of 25 patients with bullous pemphigoid that allowed for adjustments in the dose of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         based upon the clinical response found support for a corticosteroid-sparing effect [
         <a href="#rid38">
          38
         </a>
         ]. After three years, less prednisone had been taken by patients in the combination therapy group than in the group solely treated with prednisone (mean total dose of 6732 versus 3688 mg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and monitoring
         </strong>
         – A major side effect of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         therapy is myelosuppression. Examples of other potential adverse effects include malignancy, gastrointestinal disorders, infections, and hypersensitivity. Laboratory monitoring for hematologic and hepatic adverse effects is needed. The adverse effects of azathioprine are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24368242">
         <span class="h2">
          Mycophenolate mofetil
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Typical doses for
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil range from 1.5 to 2 g per day, with a maximum dose of 3 g per day. Achievement of disease control can occur within one month of treatment. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         above and
         <a class="local">
          'Determining treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serum levels of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         may vary widely among individuals given similar doses. The findings of a small, retrospective study suggest that obtaining a mycophenolic acid trough level may be helpful for patients who fail to respond to 2 g of mycophenolate mofetil per day [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The only randomized trial of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil in bullous pemphigoid was an unblinded, randomized trial of 73 patients that compared treatment with
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (0.5 mg/kg per day) plus mycophenolate mofetil (2 g per day) with methylprednisolone (0.5 mg/kg per day) plus
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (2 mg/kg per day) [
         <a href="#rid36">
          36
         </a>
         ]. The two regimens appeared similarly effective. All patients in both groups (with the exception of two patients who died and one patient who was lost to follow-up in the azathioprine group) achieved clinical remission. The differences between the mycophenolate mofetil and azathioprine groups in the mean number of days to remission (42±55 versus 24±19 days, respectively) and the mean cumulative doses of methylprednisolone (5754±9693 versus 4967±12,191 mg, respectively) were not statistically significant. However, mycophenolate mofetil was better tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Improvement in bullous pemphigoid during treatment with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil is also documented in case reports [
         <a href="#rid41">
          41-45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and monitoring
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil is often well tolerated; gastrointestinal distress is the most common side effect. An enteric-coated formulation of mycophenolate sodium has improved gastrointestinal tolerability and has appeared effective for bullous pemphigoid in several patients [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hematologic, renal, and hepatic laboratory monitoring are indicated during treatment. The adverse effects of
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643378736">
         <span class="h2">
          Methotrexate
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is typically administered at a dose of between 5 and 20 mg per week. Approaches to the initiation of treatment vary. We administer a low dose (eg, 7.5 mg per week) as initial therapy, and the drug is titrated upward (eg, weekly dose increased by 2.5 mg each month up to a maximum weekly dose of 20 mg) based upon patient tolerance and the response to therapy. Other clinicians begin with higher initial doses of methotrexate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Achievement in disease control may occur within one month of reaching a therapeutic dose (eg, 15 mg per week). (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Treatment tapering and cessation'
         </a>
         above and
         <a class="local">
          'Determining treatment failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients treated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         should also be given
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         to reduce the risk for hematologic and common gastrointestinal side effects. (See
         <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">
          "Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Folic acid supplementation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – No randomized trials have evaluated the efficacy of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in bullous pemphigoid. However, case reports and uncontrolled studies suggest that methotrexate may be beneficial when used alone or in combination with topical or systemic corticosteroid [
         <a href="#rid10">
          10,48-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 2009 retrospective review of published reports with at least 5 patients identified 62 patients with bullous pemphigoid who were treated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (5 to 25 mg per week), including 45 who received methotrexate without another systemic therapy [
         <a href="#rid51">
          51
         </a>
         ]. Among the 45 patients who received only methotrexate and a topical corticosteroid, 93 percent responded well to treatment, and all 17 patients treated with methotrexate and systemic corticosteroids achieved disease control.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The results of a subsequent retrospective study suggest that monotherapy with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         may also be effective [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and monitoring
         </strong>
         – Additional potential side effects include hepatotoxicity and pulmonary fibrosis. The side effects of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         are reviewed separately. Hematologic, hepatic, and renal monitoring are indicated during treatment. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H691465200">
         <span class="h1">
          REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biologic therapies are a treatment option for patients who fail to respond to topical corticosteroids, systemic corticosteroids, and corticosteroid-sparing agents. Although
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         use for bullous pemphigoid has been reported most frequently, data are insufficient to determine the most effective biologic therapy.
        </p>
        <p class="headingAnchor" id="H24368271">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is a humanized chimeric monoclonal antibody that targets and destroys CD20+ B and pre-B cells. Case reports and small case series indicate that rituximab may be effective for bullous pemphigoid that is refractory to conventional therapies. A 2019 systematic review of the literature that assessed reports of patients treated with rituximab (doses ranging from 375 mg/m
         <sup>
          2
         </sup>
         every one to four weeks to 500 mg weekly for two weeks) or
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         (doses ranging from 100 mg every two to four weeks to 525 mg every two weeks) found complete responses in 52 of 61 patients given rituximab (85 percent) and 16 of 19 patients given omalizumab (84 percent) [
         <a href="#rid55">
          55
         </a>
         ]. Most patients had failed to respond to systemic corticosteroid therapy prior to biologic treatment. Reports of recurrence were less frequent in patients treated with rituximab than with omalizumab (29 versus 80 percent), with mean times to recurrence of 10 and 3 months, respectively.
        </p>
        <p>
         Major side effects of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H548110257">
         <span class="h2">
          Dupilumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          Dupilumab
         </a>
         is a human anti-interleukin (IL) receptor-alpha monoclonal antibody that inhibits signaling of IL-4 and IL-13, cytokines hypothesized to play an important role in the pathogenesis of bullous pemphigoid. In a multicenter case series of 13 patients with bullous pemphigoid treated with dupilumab (600 mg initially followed by 300 mg every other week up to weekly), 12 patients (92 percent) experienced improvement and desired to continue dupilumab, and 7 patients (58 percent) achieved disease clearance (absence of bullae and pruritus). Improvement occurred within one to five months [
         <a href="#rid56">
          56
         </a>
         ]. Dupilumab has also been associated with improvement of bullous pemphigoid in case reports [
         <a href="#rid57">
          57,58
         </a>
         ]. A randomized clinical trial is underway [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3255919493">
         <span class="h2">
          Omalizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         , an anti-immunoglobulin E (IgE) monoclonal antibody, has been associated with improvement in bullous pemphigoid in case reports and case series [
         <a href="#rid60">
          60-67
         </a>
         ]. The findings of a 2019 systematic review of the literature that assessed reports of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and omalizumab use for bullous pemphigoid are reviewed above [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="local">
          'Rituximab'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1403721490">
         <span class="h2">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is occasionally utilized for the treatment of bullous pemphigoid. A 2012 review of published reports identified 45 patients (including 43 adults and 2 infants) with bullous pemphigoid who were treated with IVIG with or without concomitant immunosuppressive therapy [
         <a href="#rid68">
          68
         </a>
         ]. Most adults were treated with 2 g/kg per cycle, with cycles repeated every four weeks. Among the adult patients, 86 percent attained clinical improvement; improvement occurred within an average of three months.
        </p>
        <p>
         Although further studies are necessary to determine the optimal regimen and indications for
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , factors that have been proposed to contribute to favorable responses include multiple treatment cycles [
         <a href="#rid68">
          68,69
         </a>
         ], coadministration of an immunosuppressant [
         <a href="#rid70">
          70
         </a>
         ], and shorter durations of disease prior to the initiation of therapy [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         The beneficial effects of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         on bullous pemphigoid are supported by evidence that serum levels of bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) antibodies decline in response to treatment. In an uncontrolled study of 10 patients with bullous pemphigoid, treatment with IVIG was associated with the induction of both serologic and clinical remissions in all patients [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above.)
        </p>
        <p>
         The adverse effects of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         are reviewed separately. The high cost of IVIG limits the use of this therapy. (See
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1483971087">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data or safety concerns preclude routine use of various other therapies. Although benefit of oral Janus kinase (JAK) inhibitors for bullous pemphigoid has been suggested in case reports and a case series, data are insufficient to confirm efficacy and safety in this population [
         <a href="#rid73">
          73-76
         </a>
         ].
        </p>
        <p>
         Examples of other medications that have appeared to be of benefit for bullous pemphigoid in a small number of patients include
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         in children [
         <a href="#rid77">
          77,78
         </a>
         ], topical
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid79">
          79,80
         </a>
         ],
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid81">
          81,82
         </a>
         ],
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         [
         <a href="#rid83">
          83,84
         </a>
         ],
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid85">
          85,86
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         [
         <a href="#rid87">
          87
         </a>
         ]. A few case reports document beneficial effects of immunoadsorption in patients with refractory bullous pemphigoid [
         <a href="#rid88">
          88,89
         </a>
         ]. Data conflict on the efficacy of plasmapheresis (plasma exchange) [
         <a href="#rid37">
          37,90
         </a>
         ].
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fcond%3Dbullous%2Bpemphigoid&amp;token=8CcLkO8qdpSIZZjSTXRliHOX934G%2FoSUua4EizbYsFMH3ho1W34kHLp10cdUlFcf%2F4RJYu2SycMYcLyGgbjdfvWcSoRKHSDwJ3dlU7gKngQ%3D&amp;TOPIC_ID=15297" target="_blank">
          Trials involving other biologic and nonbiologic therapies
         </a>
         , such as
         <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">
          benralizumab
         </a>
         , efgartigimod, and the investigational drug bertilimumab, are underway.
        </p>
        <p class="headingAnchor" id="H24368306">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical course of bullous pemphigoid is variable. In general, bullous pemphigoid follows a chronic, relapsing course [
         <a href="#rid15">
          15,91-93
         </a>
         ]. Long-term remission may occur after months to years. In an early report that preceded the use of systemic corticosteroids, 8 of 30 patients entered remission after 3 to 38 months of active disease. Drug-induced bullous pemphigoid most often has a limited course following cessation of the inciting dug (see
         <a class="local">
          'Identification of drug-induced disease'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of relapse
         </strong>
         – High titers of bullous pemphigoid antigen 180 (BP180) antibodies at the time of cessation of therapy may portend an increased likelihood for disease relapse. In a prospective study of 114 patients with bullous pemphigoid, a high enzyme-linked immunosorbent assay (ELISA) anti-BP180-NC16A titer at the time of cessation of oral or topical corticosteroid therapy was an independent predictor of disease relapse within one year [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Enzyme-linked immunosorbent assay'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to high titers of BP180 antibodies at the time of cessation of therapy [
         <a href="#rid15">
          15
         </a>
         ], other factors may portend an increased risk for relapse. A one-year, prospective, multicenter, observational study of 120 patients with newly diagnosed bullous pemphigoid found that extensive disease at baseline (hazard ratio [HR] 2.37, 95% CI 1.2-4.8) and associated dementia (HR 2.09, 95% CI 1.0-4.2) were independent risk factors for disease relapse within the first year of treatment [
         <a href="#rid13">
          13
         </a>
         ]. In addition, the change in bullous pemphigoid antibody levels after the start of treatment appeared to correlate with risk for relapse. The mean decrease in BP180 antibody levels during the first 60 days of treatment was smaller among patients who relapsed than among patients who remained in remission (-10.0 versus -45.2 percent). A similar but lesser effect was observed for bullous pemphigoid antigen 230 (BP230) antibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of death
         </strong>
         – Bullous pemphigoid is a potentially fatal disease. Estimates for one-year overall mortality of patients with bullous pemphigoid have ranged from 11 to 48 percent, with most studies finding increased rates of mortality compared with subjects without bullous pemphigoid [
         <a href="#rid94">
          94-98
         </a>
         ]. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A French, prospective, cohort study of 312 patients with bullous pemphigoid found an overall one-year mortality rate of 38 percent [
         <a href="#rid95">
          95
         </a>
         ]. The risk for death was more than six times greater for patients with bullous pemphigoid than for age- and sex-matched subjects in the general population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A Swiss study that evaluated the course of bullous pemphigoid in 115 patients found probabilities of death one, two, and three years after diagnosis of 21, 28, and 39 percent, respectively. The mortality rate for patients with bullous pemphigoid was approximately three times greater than for age- and sex-matched subjects in the general population [
         <a href="#rid94">
          94
         </a>
         ]. The increase in likelihood for death was most pronounced among patients less than 70 years in age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For unknown reasons, the mortality rates reported in Europe (19 to 48 percent) [
         <a href="#rid93">
          93-95,99-104
         </a>
         ] have generally been higher than those reported in the United States (11 to 23 percent) [
         <a href="#rid94">
          94,105
         </a>
         ]. One retrospective, cohort study in the United States failed to find an increase in mortality compared with the general population [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The reasons for an increase in death among patients with bullous pemphigoid may be multifactorial. Complications secondary to therapeutic agents are likely a contributing factor. In the Swiss study, the most common causes for death were heart disease, infection, and neurologic disease [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643371701">
         <span class="h1">
          PATIENT SUPPORT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pemphigus.org%2F&amp;token=kgWnuLuwd5ywHVQww%2BY9ejelGxqgN19Ljg020%2Fmkv%2B6Jk4iV1n3Xa69uIoeLfYSW&amp;TOPIC_ID=15297" target="_blank">
          International Pemphigus and Pemphigoid Foundation
         </a>
         is a resource that provides patients and clinicians with information about bullous pemphigoid.
        </p>
        <p class="headingAnchor" id="H4037292044">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121560.html" rel="external">
          "Society guideline links: Bullous pemphigoid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H435648187">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/87300.html" rel="external">
          "Patient education: Bullous pemphigoid (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643371716">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease overview
         </strong>
         – Bullous pemphigoid is an uncommon, potentially fatal, autoimmune blistering disease that most commonly affects older adults  (
         <a class="graphic graphic_picture graphicRef70352 graphicRef72866 graphicRef79112 graphicRef78910" href="/z/d/graphic/70352.html" rel="external">
          picture 1A-D
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16864.html" rel="external">
          "Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">
          "Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to management
         </strong>
         – The management of bullous pemphigoid involves assessment for drug-induced disease and signs of ocular or internal involvement, as well as careful selection of immunomodulatory treatments that attenuate autoantibody production and antibody-mediated inflammation. Much of the morbidity and mortality related to bullous pemphigoid results from the combined effect of patient comorbidities and adverse effects of treatment, rather than from direct effects of the disease. (See
         <a class="local">
          'Treatment goals'
         </a>
         above and
         <a class="local">
          'Pretreatment assessment'
         </a>
         above and
         <a class="local">
          'Approach to management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred initial treatments
         </strong>
         – Topical corticosteroids, oral corticosteroids, and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         are the mainstays of initial treatment based upon data that support efficacy of these interventions. Selection among these treatments is influenced by the feasibility of treatment, risk for adverse effects, efficacy, and patient preference. (See
         <a class="local">
          'Overview of therapeutic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although topical corticosteroid monotherapy is effective and generally well tolerated, treatment requires application of topical corticosteroids to extensive areas of skin daily, which can be challenging for some patients (see
         <a class="local">
          'Selection of initial treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who can tolerate topical therapy
         </strong>
         – For patients with extensive bullous pemphigoid (eg, widespread skin involvement or development of many new bullae per day) who are willing and able to perform topical therapy and who prefer topical treatment, we recommend treatment with a high-potency topical corticosteroid, such as
         <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">
          clobetasol
         </a>
         0.05% cream, rather than oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). (See
         <a class="local">
          'Topical corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who cannot tolerate topical therapy
         </strong>
         – For patients who prefer to avoid extensive, daily application of topical corticosteroids or are unable to perform or receive such treatment, an oral agent should be used as the primary initial treatment (see
         <a class="local">
          'Selection of initial treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Mild disease
         </strong>
         – For patients with milder presentations of bullous pemphigoid (eg, localized bullous pemphigoid or development of only a few new bullae per day) who desire oral treatment, we suggest
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         rather than oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Doxycycline may be less likely to induce rapid remission compared with oral prednisone but has a more favorable side effect profile. We typically combine doxycycline therapy with application of a high-potency topical corticosteroid to active lesions. (See
         <a class="local">
          'Tetracyclines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Extensive disease
         </strong>
         – For patients with extensive bullous pemphigoid (eg, widespread skin involvement or development of many new bullae per day) who desire oral treatment, we suggest oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         as initial treatment rather than
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Initial treatment with doxycycline is an acceptable alternative for patients who are unlikely to tolerate systemic corticosteroid therapy or who prefer to avoid the risks of oral corticosteroid therapy. We typically combine doxycycline therapy with application of a high-potency topical corticosteroid to active lesions. (See
         <a class="local">
          'Systemic corticosteroids'
         </a>
         above and
         <a class="local">
          'Tetracyclines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Limited data suggest that
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         may also be effective as primary treatment. (See
         <a class="local">
          'Methotrexate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of corticosteroid-sparing therapies
         </strong>
         – Because bullous pemphigoid often persists for years, corticosteroid-sparing therapies, such as tetracyclines,
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          dapsone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , are often prescribed to facilitate tapering of oral corticosteroids. However, high-quality data to confirm the value of corticosteroid-sparing agents in bullous pemphigoid are lacking. (See
         <a class="local">
          'Corticosteroid-sparing therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – Biologic therapy may be useful for the management of patients who fail standard therapy. (See
         <a class="local">
          'Refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The clinical course of bullous pemphigoid is variable. Remission may occur after months or years. Certain characteristics, such as a high titer of bullous pemphigoid antigen 180 (BP180) antibodies at the time of treatment cessation, may be associated with increased risk for relapse. Bullous pemphigoid is a potentially fatal disease. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol 2016; 91:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol 2018; 154:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verheyden MJ, Bilgic A, Murrell DF. A Systematic Review of Drug-Induced Pemphigoid. Acta Derm Venereol 2020; 100:adv00224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsiogka A, Bauer JW, Patsatsi A. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. Acta Derm Venereol 2021; 101:adv00377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plaquevent M, Tétart F, Fardet L, et al. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J Invest Dermatol 2019; 139:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prugnit-Rouanet M, Delaumenie S, Couraud A, et al. Gliptin-induced bullous pemphigoid: withdrawal of gliptin allows for faster control of the disease. Eur J Dermatol 2022; 32:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008; 144:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol 2014; 150:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izumi T, Ichiki Y, Esaki C, Kitajima Y. Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. J Dermatol 2004; 31:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell LS, Chevalier M, Levy RA, Rhodes A. Hypothalamic-pituitary-adrenal axis suppression related to topical glucocorticoid therapy in a child with psoriatic exfoliative erythroderma. Pediatr Dermatol 2012; 29:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreno B, Sassolas B, Lacour P, et al. [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann Dermatol Venereol 1993; 120:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; :CD002292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morel P, Guillaume JC. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Ann Dermatol Venereol 1984; 111:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012; 32:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995; 133:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goon AT, Tan SH, Khoo LS, Tan T. Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. Singapore Med J 2000; 41:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas I, Khorenian S, Arbesfeld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safa G, Darrieux L. Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases. J Am Acad Dermatol 2011; 64:e116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirtschig G, Khumalo NP. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol 2004; 5:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 2017; 177:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996; 34:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978; 2:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sokumbi O, el-Azhary RA, Langman LJ. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. J Am Acad Dermatol 2013; 68:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox JC, Kenkare S, Petronic-Rosic V, et al. Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy. Pediatr Dermatol 2010; 27:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin 2011; 29:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhm M, Beissert S, Schwarz T, et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tursen U, Guney A, Kaya T, Ikizoglu G. Treatment of bullous pemphigoid with enteric-coated mycophenolate sodium. J Eur Acad Dermatol Venereol 2007; 21:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006; 17:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2013; 24:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunay U, Gunduz K, Ermertcan AT, Kandiloğlu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol 2013; 32:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heilborn JD, Ståhle-Bäckdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139:1506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas P, Giacaman P, Fernández J, Morales C. Bullous pemphigoid associated with psoriasis: a good response to methotrexate. An Bras Dermatol 2019; 94:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kremer N, Snast I, Cohen ES, et al. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature. Am J Clin Dermatol 2019; 20:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J Am Acad Dermatol 2020; 83:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol 2018; 154:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J 2019; 25.
          </a>
         </li>
         <li class="breakAll">
          A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (LIBERTY-BP). https://clinicaltrials.gov/ct2/show/NCT04206553 (Accessed on April 11, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 2012; 148:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 2014; 71:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lonowski S, Sachsman S, Patel N, et al. Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Rep 2020; 6:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balakirski G, Alkhateeb A, Merk HF, et al. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol 2016; 30:1778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalcin AD, Genc GE, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab 2014; 60:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menzinger S, Kaya G, Schmidt E, et al. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid. Acta Derm Venereol 2018; 98:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vico-Alonso C, Calleja-Algarra A, Aragón-Miguel R, et al. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. Dermatol Ther 2019; 32:e12829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity 2012; 45:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chee SN, Murrell DF. The use of intravenous immunoglobulin in autoimmune bullous diseases. Immunol Allergy Clin North Am 2012; 32:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008; 144:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaitanis G, Alexis I, Pelidou SH, et al. High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol 2012; 22:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003; 17:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan B, Wang M. Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases. Br J Dermatol 2023; 188:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep 2023; 32:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youssef S, Gallitano S, Bordone LA. Two cases of bullous pemphigoid effectively treated with oral tofacitinib. JAAD Case Rep 2023; 32:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther 2022; 35:e15754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majmudar V, Herath D, O'Toole EA, Harrison A. Bullous pemphigoid of childhood: a rare disease with diagnostic and management challenges. Clin Exp Dermatol 2010; 35:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox BJ, Odom RB, Findlay RF. Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects. J Am Acad Dermatol 1982; 7:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calcaterra R, Carducci M, Franco G, et al. Topical tacrolimus treatment for localized pretibial bullous phemphigoid. J Eur Acad Dermatol Venereol 2009; 23:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko MJ, Chu CY. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003; 149:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curley RK, Holden CA. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin Exp Dermatol 1991; 16:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chave TA, Mortimer NJ, Shah DS, Hutchinson PE. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004; 151:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilabert A, Lozano F, Iranzo P, et al. A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis? J Am Acad Dermatol 2011; 65:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997; 137:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000; 136:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ino N, Kamata N, Matsuura C, et al. Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1997; 1:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller PA, Bröcker EB, Klinker E, et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 2012; 224:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; 2:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol 2009; 145:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortés B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gual A, Mascaró JM Jr, Rojas-Farreras S, et al. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol 2014; 28:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cai SC, Allen JC, Lim YL, et al. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. Br J Dermatol 2014; 170:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Kim SC. Mortality of patients with bullous pemphigoid in Korea. J Am Acad Dermatol 2014; 71:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard P, Enginger V, Venot J, et al. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol 1995; 122:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005; 153:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122:1091.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15297 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27828632" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30090931" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24404939" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Drug-induced pemphigoid: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32176310" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A Systematic Review of Drug-Induced Pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426566" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30543900" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36065541" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Gliptin-induced bullous pemphigoid: withdrawal of gliptin allows for faster control of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11821508" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28279484" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18490587" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A retrospective analysis of patients with bullous pemphigoid treated with methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10677092" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12443845" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24226428" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187305" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451497" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056920" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21955378" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Autoimmune bullous skin diseases. Part 1: Clinical manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19177141" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21995486" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hypothalamic-pituitary-adrenal axis suppression related to topical glucocorticoid therapy in a child with psoriatic exfoliative erythroderma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8349876" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4251769" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8304707" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20927731" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Interventions for bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6395773" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22560141" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Corticosteroid use in autoimmune blistering diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7669647" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Bullous pemphigoid successfully controlled by tetracycline and nicotinamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11026799" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2940979" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8002646" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Nicotinamide and tetracycline therapy of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8425974" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of generalized bullous pemphigoid with oral tetracycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21571156" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15554733" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Management of bullous pemphigoid: recommendations for immunomodulatory treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28494097" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19824739" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8601662" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18087004" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420491" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/363229" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Azathioprine plus prednisone in treatment of pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/329769" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22884445" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20807355" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bullous pemphigoid in late childhood successfully treated with mycophenolate mofetil as an adjuvant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21924997" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mycophenolate mofetil for the management of autoimmune bullous diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10365927" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9048797" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bullous pemphigoid treated with mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738791" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Successful therapy for bullous pemphigoid with mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17373988" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of bullous pemphigoid with enteric-coated mycophenolate sodium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17853312" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of refractory blistering autoimmune diseases with mycophenolic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268701" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bullous pemphigoid: a case series with emphasis on long-term remission off therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777222" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429144" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19548961" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10321603" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14623719" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Methotrexate for bullous pemphigoid: preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31090831" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Bullous pemphigoid associated with psoriasis: a good response to methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30421306" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32179082" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30140849" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32045153" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Dupilumab for bullous pemphigoid with intractable pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32045153" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Dupilumab for bullous pemphigoid with intractable pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23165827" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Successful treatment of bullous pemphigoid with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19152970" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24954907" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Omalizumab therapy for bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32140524" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Increasing evidence for omalizumab in the treatment of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27357866" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24697134" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29136264" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30659716" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21923613" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22560145" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The use of intravenous immunoglobulin in autoimmune bullous diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18490594" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22548754" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14761129" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36763722" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36691588" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36691585" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Two cases of bullous pemphigoid effectively treated with oral tofacitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35920701" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20447089" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Bullous pemphigoid of childhood: a rare disease with diagnostic and management challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6754772" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Erythromycin therapy in bullous pemphigoid: possible anti-inflammatory effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18410329" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Topical tacrolimus treatment for localized pretibial bullous phemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14632824" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Topical tacrolimus therapy for localized bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2025943" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Steroid-resistant bullous pemphigoid treated with cyclosporin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2857378" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Effects of cyclosporin on bullous pemphigoid and pemphigus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541099" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Chlorambucil as a steroid-sparing agent in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2189909" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The use of chlorambucil in the treatment of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22000875" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: implications for pathogenesis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415254" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11030765" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10225735" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Immunoadsorption for the treatment of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22678083" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6147549" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Plasma exchange in bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19770439" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mortality of bullous skin disorders from 1979 through 2002 in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18707800" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554299" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : High risk of death in elderly patients with extensive bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21574978" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Mortality of bullous pemphigoid in Switzerland: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22418872" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Incidence and mortality of bullous pemphigoid in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23279207" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24372558" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24930586" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Mortality of patients with bullous pemphigoid in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1597545" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Lack of predictive factors for the clinical course of bullous pemphigoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8729818" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : [Survival prognosis in pemphigoid. A cohort analysis of 78 patients].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12071817" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15967914" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Prediction of survival for patients with bullous pemphigoid: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16086760" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18614511" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15140208" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Mortality rate of bullous pemphigoid in a US medical center.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
